Ductal carcinoma in situ - update on risk assessment and management

Jia-Min B Pang; Kylie L Gorringe; Stephen B Fox

doi:10.1111/his.12796

Ductal carcinoma in situ - update on risk assessment and management

Histopathology. 2016 Jan;68(1):96-109. doi: 10.1111/his.12796.

Authors

Jia-Min B Pang^{1

2}, Kylie L Gorringe^{2

3

4}, Stephen B Fox^{1

2

3}

Affiliations

¹ Department of Pathology, Peter MacCallum Cancer Centre, East Melbourne, Vic., Australia.
² Department of Pathology, University of Melbourne, Melbourne, Vic., Australia.
³ Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Vic., Australia.
⁴ Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Vic., Australia.

PMID: 26768032
DOI: 10.1111/his.12796

Abstract

Ductal carcinoma in situ (DCIS) accounts for ~20-25% of breast cancers. While DCIS is not life-threatening, it may progress to invasive carcinoma over time, and treatment intended to prevent invasive progression may itself cause significant morbidity. Accurate risk assessment is therefore necessary to avoid over- or undertreatment of an individual patient. In this review we will outline the evidence for current management of DCIS, discuss approaches to DCIS risk assessment and challenges facing identification of novel DCIS biomarkers.

Keywords: breast neoplasms; clinical markers; clinical pathology; patient care management.

Publication types

Review

MeSH terms

Breast Neoplasms / pathology*
Carcinoma, Intraductal, Noninfiltrating / pathology*
Disease Management*
Disease Progression
Female
Humans
Risk Assessment